Introduction
As the mammalian central nervous system (CNS) matures, it loses its ability to repair itself. Alongside the inhibitory environment characterized by a glial scar and an upregulation of inhibitory proteins such as chondroitin sulphate proteoglycans (CSPGs) and myelin-associated glycoproteins (MAGs), CNS axons have an intrinsically low capacity for self-repair which continually diminishes with age (Reviewed by Chew et al., 2012) . As neurons mature, proteins that were once key regulators of axon guidance and elongation are downregulated resulting in a reduced capacity for axonal repair after injury. By recapitulating neuronal expression of growth-promoting proteins, such as integrins, transmembrane receptors involved in mediating cell-cell and cell-matrix interactions, neurite outgrowth and axon regeneration can be significantly enhanced (Condic, 2001; Andrews et al., 2009; . The α9β1 integrin heterodimer, for example, is highly expressed during CNS development aiding growth cone formation and axonal elongation but is downregulated in mature CNS axons. It binds the main extracellular matrix (ECM) glycoprotein of the CNS, tenascin-C, which is highly upregulated after injury and has been a recent target of axonal regeneration research (Andrews et al., 2009; Chen et al., 2010; Cheah et al., 2016) . For example, increasing expression of the alpha9 subunit in adult dorsal root ganglion (DRG) neurons alongside its activator Kindlin-1, has been shown to promote growth cone formation and regeneration of severed axons after dorsal root injury . Despite these promising findings, recent data reveals region-specific and age-specific differences exist resulting in variations in integrin trafficking into the axonal compartment (Franssen et al., 2015; Andrews et al., 2016 ) creating yet another hurdle for regeneration.
Blockage of Integrin Localization into the Axonal Compartment
In newly published work, Andrews et al. (2016) highlight differences in integrin localization in distinct neuronal subtypes, following viral vector-based expression. Their findings show that in mature corticospinal tract (CST) and rubrospinal tract (RST) axons, exogenously-expressed integrins are not localized or transported into the axonal compartment, remaining instead in the somatodendritic compartment . On the other hand,
Abstract
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Current Approaches to CNS Repair
A number of experimental avenues have been pursued with the hope of finding a robust treatment to promote axonal regeneration within the CNS (Figure 1) . Treatments include modification of ECM components, such as through the removal of CSPGs, to stimulate neuronal plasticity, and removal of inhibitory proteins, such as Nogo-A, to alleviate degradation and apoptotic pathways (Reviewed by Chew et al., 2012) . Furthermore, cellular replacement therapies and application of biomaterials to stabilize lesion architecture have also been utilized as therapies for CNS repair (Reviewed by Assunção-Silva et al., 2015) . In addition, a number of signalling pathways involved in maintaining axonal growth, guidance, trafficking, receptor turnover and apoptosis, including neurotrophic factors and other growth-promoting receptors such as integrins, have provided several targets for viral vector-based gene therapy to promote intrinsic regeneration following axonal injury.
Figure 1 Current approaches for promoting axonal repair following central nervous system (CNS) injury.
Schematic diagram highlighting an overview of axonal injury and degradation at the lesion site along with current approaches to enhance repair. After CNS injury, an inhibitory lesion site is created surrounded by reactive astrocytes and a number of growth-inhibiting proteins including CSPGs and Nogo. Transport within axons is mediated by both kinesin and dynein motors and allows cargo-carrying vesicles to travel in both anterograde and retrograde directions. However, within the mature CNS many growth-promoting proteins, such as TrkB, are trafficked back to the cell body in the retrograde direction resulting in a reduced ability of axons to regenerate after injury. (1) Modification of the ECM using ChABC enzyme to degrade CSPGs or anti-Nogo A antibodies to inhibit Nogo activity can reduce the action and signalling of inhibitory components in the injury site to promote axonal regeneration after injury. (2) Biomaterials can be used to stabilize the lesion site as well as provide guidance channels for axon regrowth. Modified scaffolds have been used to deliver multiple neurotrophic factors to lesion site to aid axon repair. (3) Alternatively, delivery of viral vectors that are tissue or cell-specific can carry DNA encoding for growth-promoting proteins e.g., TrkB to the lesion site. Using gene therapy to reinstate proteins involved in axon growth and guidance can prompt growth-promoting signalling pathways. (4) Cell therapy involves replacing lost or damaged cells at the lesion site. These can include OECs to promote remyelination of injured axons or transplantation of NSCs to replace injured neurons/axons. ChABC: Chondroitinase ABC; CSPGs: chondroitin sulphate proteoglycans; ECM: extracellular matrix; NPC: neural progenitor cell; NSC: neural stem cell; OECs: olfactory ensheathing cells; TrkB: tropomyosin receptor kinase B.
Failed Axonal Transport of Signalling Molecules in CNS Repair
Current research has focused on targeting and reinstating regenerative signalling pathways associated with neurite outgrowth and survival, such as tropomyosin-related kinase (Trk) receptors, insulin-like growth factor 1 (IGF-I) receptors and integrin receptors following injury. Advancements in viral vector research have made gene therapy a commonly used experimental tool to study regenerative signalling pathways together with axonal repair. Research suggests expression levels of endogenous TrkB in injured CST axons are not sufficient to promote neurite outgrowth and repair (Lu et al., 2001 ) however nowever forced expression of TrkB using lentiviral vectors following CST lesioning resulted in enhanced regeneration (Hollis et al., 2009) . In that study, however, Hollis et al. (2009) demonstrated that exogenously expressed TrkB was only localized as far as the proximal part of CST axons (subcortical white matter) suggesting that intrinsic transport mechanisms within these axons are compromised in the adult nervous system. Axonal transport and localization of growth-promoting molecules involved in neuronal signalling are necessary and essential for the development of the nervous system as well as for axon growth and homeostasis. Long-distance transport is driven by kinesin and dynein motors which are regulated by Rab GTPases, kinases and a number of scaffolding proteins (Maday et al., 2014) . Failure of axon transport can have a detrimental effect on axon growth and function and has been linked to disease and injury, such as in motor neuron disease, Alzheimer's disease, and spinal cord injury (SCI). Research now suggests that axon transport and localization in certain neuronal regions is inherently downregulated as the normal uninjured CNS matures . Furthermore, evidence suggests growth-promoting receptors are excluded from mature CST axons, including TrkB, the receptor for brain-derived neurotrophic factor (BDNF) (Lu et al., 2001 ) and integrins (Franssen at al., 2015; Andrews et al., 2016) .
Use of Biomaterials to Bridge CNS Lesion Sites
Not only is it necessary to consider localization of virally-expressed proteins in neurons, viral vectors themselves may have limited temporal expression, although more treatments currently utilize standard adeno-associated virus or lentivirus which have been shown to have long-term sustained expression. The literature suggests however that by combining gene therapy with biomaterials, better longterm expression may result (Thomas et al., 2014) . Scaffold bridges made from poly(lactide-co-glycolide) (PLG) have been used to deliver lentiviral vectors carrying sonic hedgehog (Shh) and neurotrophin-3 to T 9 /T 10 region of spinal cords of mice following lateral hemisection (Thomas et al., 2014) . Results demonstrate that expression of both proteins was sustained at the injury site, promoting axonal regrowth through the bridge architecture as well as facilitating recruitment of endogenous oligodendrocyte precursors and Schwann cells. This also resulted in increased axonal myelination 8 weeks post-transplant. Use of biodegradable bridges that contain a channel network for axonal guidance allows for localized delivery of multiple transgenes to the injury site, however, delivery of scaffolds can be invasive and does not overcome the inhibitory milieu created after injury. Likewise, there are also cases where sustained expression of virally-expressed proteins is unnecessary. In these cases, tamoxifen-inducible systems would overcome issues in regulating expression.
Modification of CNS Extracellular Matrix to Promote Axonal Growth
Restoring intracellular signalling pathways is one approach to tackle the failure in axon repair however we can also target removal of inhibitory proteins. The lesion environment consists of proteins that are known to prevent axonal regeneration including CSPGs and myelin-derived inhibitory proteins, such as Nogo, MAG and oligodendrocyte-myelin glycoprotein (OMgp). Removing or inactivating inhibitory molecules by blocking their action has shown efficacy in promoting regeneration. These strategies include application of the bacterial enzyme, chondroitinase ABC (ChABC) to digest glycosaminoglycan side chains of CSPGs and monoclonal antibodies against Nogo-A to inhibit Nogo activity. Research indicates a combination of treatments may provide the best recovery after axonal injury. Indeed, combined administration of anti-Nogo-A antibodies by intrathecal infusion, and ChABC by intraspinal injections and intrathecal infusion, alongside behavioral rehabilitation was shown to promote axonal regeneration and functional recovery following SCI, more than either treatment alone (Zhao et al., 2013) . Unfortunately, administration of both molecules is invasive with ChABC requiring multiple applications to maintain the level of enzymatic activity required for axonal regeneration and sprouting.
Cellular Grafting to Reconnect Damaged Pathways
Bridging SCI lesion sites with cellular replacement therapies including oligodendrocytes and Schwann cells to encourage remyelination, as well as astrocytes and neural stem cells to replace lost cells is another avenue that has resulted in successful regeneration following damage. Research suggests however that a lesion environment can affect transplanted cell survival, engraftment, migration, proliferation and the availability of differentiation and growth promoting cues (Sontag et al., 2014) . This study suggests that cell transplant treatments need to be combined with tandem therapies to utilize ECM environment to support and promote the grafted cells in vivo. Indeed, combining a neural stem cell (NSC) graft with ChABC enzyme to degrade CSPGs can promote graft survival, regeneration, axonal plasticity and functional recovery in a chronic animal model of SCI (Karimi-Abdolrezaee et al., 2010) .
Age and Neuronal Type Dictates Axonal Transport and Localization
Research indicates that there are age-associated changes within CNS axonal transport, including a decrease in anterograde trafficking (Milde et al., 2015) . Interestingly this decrease in transport in mature neurons can be partially reversed within peripheral nerves (Milde et al., 2015) . Notably age-associated changes in axonal transport are also region specific, with differing transport rates in different neuronal areas, such as optic nerve, sciatic nerve and areas of the hippocampus (Milde et al., 2015) . This brings us back to the current study. Andrews et al. (2016) showed developing motor and sensory neurons have the ability to traffic growth-promoting integrins within the axonal compartment but only sensory neurons of the PNS, specifically neurons of the DRG and retinal ganglion cells (RGCs), retain this ability as they mature. In the case of mature CST and RST axons, integrins are excluded and instead are retained within the somatodendritic compartment. This work confirms observations of Milde et al. (2015) that there are region-specific differences in axonal transport, but also indicates there are age-related changes. This suggests that treatment for CNS damage would not be the same for every injury and would likely have to be modified to target injuries in different neuronal regions.
Conclusion
Together this work emphasizes promoting transport and expression of growth-promoting proteins can prompt axon repair however, a better awareness of the mechanisms required for targeting delivery into CNS axons remains. The answer to this problem may include a combination of several approaches such as biomaterials and nanoparticles, cell replacement, modification of ECM, and gene therapy. Viral vectors allow for long-term gene expression however there is a small risk of insertional mutagenesis which keeps many of these techniques currently out of clinical trials. As researchers we need to consider how these age-related and site-specific changes in axon transport can tailor our approaches for repair. This includes CNS delivery methods as research indicates different viral vectors transduce DRGs differently (Mason et al., 2010) . The question is not, do we need to re-establish axon transport, but rather how can it be done in a controlled site-specific, age-specific manner. Within this review we have discussed how reinstating age-associated changes in signalling pathways can lead to enhanced repair after injury, but when it comes to CNS injury this is only half the battle. A combination of treatments that target the milieu of injury-induced proteins to alleviate inhibitory signalling alongside region-specific modification of target signalling pathways together with physical rehabilitation is likely to offer the best hope for robust functional recovery after CNS injury.
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